In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies

Autor: David D. Ho, Chasity D. Andrews, Rachel A. Liberatore, Yaoxing Huang
Rok vydání: 2020
Předmět:
0301 basic medicine
Time Factors
Epidemiology
medicine.medical_treatment
Review
Antibodies
Viral
medicine.disease_cause
Communicable Diseases
Emerging
Mice
antivirals
Drug Discovery
Pandemic
gene transfer
Coronavirus
biology
Antibodies
Monoclonal
emerging infectious disease
General Medicine
DNA therapeutics
Infectious Diseases
Emerging infectious disease
Antibody
Coronavirus Infections
Post-Exposure Prophylaxis
electroporation
medicine.medical_specialty
medicine.drug_class
Pneumonia
Viral
030106 microbiology
Immunology
Neutralizing antibodies
Antiviral Agents
Microbiology
antibody cocktail
03 medical and health sciences
Virology
medicine
Animals
Humans
Post-exposure prophylaxis
Intensive care medicine
Pandemics
Biological Products
business.industry
COVID-19
Outbreak
DNA
030104 developmental biology
Infectious disease (medical specialty)
biology.protein
Parasitology
Antiviral drug
business
Zdroj: Emerging Microbes & Infections
article-version (VoR) Version of Record
ISSN: 2222-1751
Popis: With increasing frequency, humans are facing outbreaks of emerging infectious diseases (EIDs) with the potential to cause significant morbidity and mortality. In the most extreme instances, such outbreaks can become pandemics, as we are now witnessing with COVID-19. According to the World Health Organization, this new disease, caused by the novel coronavirus SARS-CoV-2, has already infected more than 10 million people worldwide and led to 499,913 deaths as of 29 June, 2020. How high these numbers will eventually go depends on many factors, including policies on travel and movement, availability of medical support, and, because there is no vaccine or highly effective treatment, the pace of biomedical research. Other than an approved antiviral drug that can be repurposed, monoclonal antibodies (mAbs) hold the most promise for providing a stopgap measure to lessen the impact of an outbreak while vaccines are in development. Technical advances in mAb identification, combined with the flexibility and clinical experience of mAbs in general, make them ideal candidates for rapid deployment. Furthermore, the development of mAb cocktails can provide a faster route to developing a robust medical intervention than searching for a single, outstanding mAb. In addition, mAbs are well-suited for integration into platform technologies for delivery, in which minimal components need to be changed in order to be redirected against a novel pathogen. In particular, utilizing the manufacturing and logistical benefits of DNA-based platform technologies in order to deliver one or more antiviral mAbs has the potential to revolutionize EID responses.
Databáze: OpenAIRE
Externí odkaz: